Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol's Strong SITC: IDO, 1L Kidney Cancer And New Mechanism Data Bode Well

Executive Summary

In the CheckMate 214 study in first-line renal cell carcinoma, Bristol's Opdivo/Yervoy combo beat Pfizer's Sutent on overall survival endpoint regardless of PD-L1 expression, supporting a bid for expanded labeling.

Advertisement

Related Content

Opdivo And Eliquis Carry Bristol’s Q1; Company Continues To Defend IO Strategy
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
Keeping Track: A Fresh Wave Of Approvals
In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts
Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense
Scrip's Rough Guide To IL-2: Mother Of All Cytokines
Nektar's NKTR-214 IO Deal With Bristol Looks Even Sweeter With More Data
Pharma Q4 Results Preview: Bristol, Allergan, Gilead, GSK, Sanofi, Teva
No Clear Winner in BMS, Exelixis/Ipsen First-line Renal Cancer Race
IDO Emerges As Clean Combo Partner, Rising Star At AACR

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099863

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel